Share on StockTwits

XOMA Corp (NASDAQ:XOMA) CMO Paul D. Rubin sold 11,580 shares of XOMA Corp stock on the open market in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $4.54, for a total transaction of $52,573.20. Following the completion of the transaction, the chief marketing officer now directly owns 72,021 shares of the company’s stock, valued at approximately $326,975. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Shares of XOMA Corp (NASDAQ:XOMA) traded up 0.21% on Wednesday, hitting $4.88. The stock had a trading volume of 1,881,399 shares. XOMA Corp has a 52 week low of $3.31 and a 52 week high of $9.57. The stock’s 50-day moving average is $4.1 and its 200-day moving average is $5.90. The company’s market cap is $521.7 million.

XOMA Corp (NASDAQ:XOMA) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.23) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.17) by $0.06. The company had revenue of $3.41 million for the quarter, compared to the consensus estimate of $7.40 million. During the same quarter last year, the company posted ($0.30) earnings per share. XOMA Corp’s revenue was down 63.9% compared to the same quarter last year. On average, analysts predict that XOMA Corp will post $-0.65 earnings per share for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Wedbush raised their price target on shares of XOMA Corp to $14.00 in a research note on Monday, May 12th. They now have an “outperform” rating on the stock. Analysts at MLV & Co
upgraded shares of XOMA Corp from a “hold” rating to a “buy” rating in a research note on Tuesday, April 29th. They now have a $7.00 price target on the stock. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $9.11.

XOMA Corporation (NASDAQ:XOMA) is engaged in the discovery and development of antibody-based therapeutics.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.